Information Provided By:
Fly News Breaks for March 30, 2016
BMRN
Mar 30, 2016 | 08:30 EDT
Leerink views the risk/reward on shares of BioMarin as positive into the company's R&D day on April 20. The analyst believes investors are most focused on Phase I BMN270 data for hemophilia A and longer duration/higher dose vosoritide data. He reiterates on Outperform rating on the shares with a $120 price target.
News For BMRN From the Last 2 Days
There are no results for your query BMRN